DealsMay 4, 2026, 06:21 AM
Apimeds US Settles Merger Disputes, Lokahi Contributes $4M, Forms Newco
AI Summary
Apimeds Pharmaceuticals US, Inc. (APUS) and its subsidiaries, along with Lokahi Therapeutics, Inc., entered into a Confidential Settlement and Mutual Release Agreement with Inscobee Inc. and Apimeds Inc. This agreement resolves all outstanding disputes stemming from the December 2025 Merger Agreement. Key terms include Lokahi retaining the Apitox program and providing a $4 million working capital contribution, while forgiving $750,000 in prior advances. APUS will also form a new subsidiary, Newco, with a planned spin-off, and distribute 51% of Lokahi's common stock. The settlement also includes conditions for potential merger unwind tied to the 2025 Form 10-K filing and audit.
Key Highlights
- Apimeds US, MindWave, Lokahi, and Inscobee Parties settled all disputes from the December 1, 2025 Merger Agreement.
- Lokahi Therapeutics will retain all rights to the Apitox program, including a $2.2 million Prevail CRO credit facility.
- Lokahi will transfer $4,000,000 as a working capital contribution to Apimeds US.
- Lokahi will forgive $750,000 in amounts previously advanced to Apimeds US or its subsidiaries.
- Apimeds US will distribute 51% of Lokahi common stock to Erik Emerson, retaining 49%.
- Apimeds US will form a new wholly-owned subsidiary, Newco, with 10% of investor financing allocated to it.
- Newco is expected to be spun off from Apimeds US within 12 months, with a potential 12-month extension.
- Merger unwind conditions include timely filing of the 2025 Form 10-K and an unqualified audit opinion.